Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Changing to DuoTrav in Patients Uncontrolled on Timolol

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of ocular hypertension, primary open-angle glaucoma or pigmentary glaucoma;~* Intraocular pressure (IOP) of between 19 to 35 mmHg at any time of the day in at least one eye (designated as the study eye);~* On a stable medication regimen for IOP reduction one week prior to the screening visit;~* Best corrected visual acuity better than 20/200 (Snellen) or 1.0 (logMAR) in each eye;~* Sign informed consent;~* Other protocol-defined inclusion criteria may apply.~Exclusion Criteria:~* Known medical history of allergy, hypersensitivity or low tolerance to any of the components of DuoTrav®;~* Any abnormality that would preclude the reliable performance of applanation tonometry in either eye;~* Infection in either eye;~* Conventional or laser intraocular surgery in either eye 3 months prior to screening visit;~* Risk for visual field or visual acuity worsening, in the opinion of the investigator;~* Women of childbearing potential;~* Pregnant or lactating women;~* Any condition that, in the opinion of the principal investigator, could interfere with participation in the study, or that could present a risk to the participant.~* Participation in another clinical study within 30 days before the screening visit;~* Other protocol-defined exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DuoTrav (Type: EXPERIMENTAL): Travoprost 0.004%/timolol maleate 0.5% fixed combination, one drop to the study eye nightly for up to 6 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).